"i didn't see a direct link between shRNA GT and the bluebird programme yet, but it's warm, very warm."
John Maranganore (CEO Alnylam) is on Bluebird's BOD. They would likely collaborate with Alnylam (as they have a cross-licence agreement with BLT) rather than BLT directly.
Of course, any drug Bluebird developed using ddRNAi would be subject to royalties to BLT.
